Date: February 17, 2022
Time: 7:00 PM Central
Moderators: José Gaston Guillem, MD, MPH, MBA, Kelli Bullard Dunn, MD, FACS, FASCRS
Presenters: Matthew F. Kalady, MD, Zhaohui Jin, MD, Timothy M. Pawlik, MD, PhD, MPH, Arvind Dasari, MD
CME Credit Hours Available: 1
There has been increasing understanding of the importance of the role of genetics in colorectal cancer and its implications in response to various treatment options as well as prognosis. This webinar will aim to present an up to date summary on the current knowledge of the impact of genetics in the treatment of colorectal cancer.
At the conclusion of this session, participants should be able to:
Jose G. Guillem is Professor of Surgery and Chief of the GI Surgery Division at UNC-Chapel Hill. He has a long standing interest in and has published extensively on early age-of-onset and hereditary forms of colorectal cancer. He is Past-President of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Dr. Guillem obtained his General Surgery training at Columbia Presbyterian Medical Center and his Colorectal Fellowship at the Lahey Clinic.
- Understand the key aspects of role genetics in colorectal cancer.
- Be able to choose best treatment options based on better understanding of colorectal cancer genetics.
- Offer individualized treatment options for patients in view of impact of tumor genetics on recurrence and survival in colorectal cancer.
Dr. Kelli Bullard Dunn received her bachelor’s degree from Stanford University and her medical degree from Harvard Medical School in 1992. She then completed her general surgery residency at the University of California, San Francisco and a fellowship in colon and rectal surgery at the University of Minnesota, where she was on the faculty from 2001 until 2005. She was recruited Roswell Park Cancer Institute in Buffalo, NY, in 2005, and became the Institute’s Chief of Colon and Rectal Surgery in 2009. Bullard Dunn joined the faculty of the University of Louisville in October 2011 where she is a Professor of Surgery. She currently serves as Vice Dean for Community Engagement and Diversity. She is board certified in both general surgery and in colon and rectal surgery, and has longstanding interest in the diagnosis and treatment of colorectal and anal cancers, precancerous conditions, hereditary malignancies, and other colorectal conditions.
Dr. Matthew Kalady is a Professor of Surgery at The Ohio State University in Columbus, OH. He graduated cum laude from Harvard College and received his medical doctorate from Duke University. He completed his general surgery training at Duke University Medical Center and subsequently completed a colorectal surgery fellowship at Cleveland Clinic, where he remained as faculty for 14 years. There he served as the Director of the Comprehensive Colorectal Cancer Program; and the Director of the Sanford R. Weiss, MD, Center for Hereditary Colorectal Neoplasia. He recently joined Ohio State where he is the Chief of the Division of Colon & Rectal Surgery, and the Medical Director of Clinical Cancer Genetics at the James Cancer Center. He is an NIH/NCI-funded basic science researcher focusing on colorectal cancer genetics, and has published more than 225 peer-reviewed articles. His main clinical interests are colorectal cancer, hereditary syndromes, and minimally invasive surgery.
Dr. Jin completed his medical training in Beijin, China. He came to the United States initially as a research fellow at University of Floridathe in 2002 then worked at the Children's Hospital Boston, Harvard Medical School as an instructor. Dr. Jin then completed his residency in New Jersey and his hematology/medical oncology fellowship at the university of Iowa. Dr. Jin had his advanced GI oncology fellowship at Mayo clinic in 2016. He has been an assistant professor at the department of medical oncology focusing on gastrointestinal malignancies at Mayo Clinic Rochester since 2019.
Dr. Pawlik received his undergraduate degree from Georgetown University and his medical degree from Tufts University School of Medicine. Dr. Pawlik completed surgical training at the University of Michigan Hospital and spent two years at the Massachusetts General Hospital as a surgical oncology research fellow. He then went on for advanced training in surgical oncology at The University of Texas M. D. Anderson Cancer Center in Houston. Dr. Pawlik’s main clinical interests include alimentary tract surgery, with a special interest in hepatic, pancreatic and biliary diseases. Dr. Pawlik also has an interest in medical ethics and completed a fellowship in medical ethics at the Harvard School of Public Health as well as a Masters in Theology from Harvard Divinity School in Boston. In addition, Dr. Pawlik was the recipient of a Clinical and Translational Science Award (CTSA) KL2 Research Scholar Award and received a PhD from the Johns Hopkins Bloomberg School of Public Health in Clinical Investigations. Dr. Pawlik is currently enrolled in the Executive MBA Program at The Ohio State University Fisher Business School.
Arvind Dasari is a medical oncologist in the Dept of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center . As a member of Southwest Oncology Group (SWOG) and NRG Oncology, he serves on their GI and Colorectal Cancers Committees. His primary research focus is in phase I-III clinical trial development using novel therapeutics inclusive of blood and tissue correlatives for biomarker discovery and enhanced drug utilization in the treatment of gastrointestinal malignancies with a focus on colorectal and neuroendocrine cancers. He has been involved in and have helped lead cooperative group, pharmaceutical, and CTEP trials.
The American Society of Colon and Rectal Surgeons (ASCRS) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits(s)TM upon successful completion.